Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

https://finance.yahoo.com/news/fite-biopharma-present-namodenoson-anti-120000906.html


Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York City.

Presentation Details:

Event: BIO CEO & Investor Conference 2025

Date & Time: February 10, 2025, at 3:45 pm EST

Location: New York Marriott Marquis, New York City

Presenter: Motti Farbstein, Chief Executive & Chief Financial Officer

During the conference, Can-Fite's management team will engage in one-on-one meetings with investors and potential partners to discuss the company’s business strategy, recent clinical milestones, and upcoming development plans. To register for the conference and schedule a one-on-one meeting with Can-Fite management, please use the link HERE.

Can-Fite’s pipeline includes advanced-stage drug candidates targeting unmet medical needs in oncology, metabolic diseases, and inflammatory conditions. The company’s lead drug candidate, Namodenoson, is in a pivotal Phase III trial for advanced liver cancer and a Phase IIb study for Metabolic Dysfunction-associated Steatohepatitis (MASH). Additionally, Piclidenoson is preparing to advance into a pivotal Phase III trial for psoriasis.